Clear, sourced knowledge about peptides.Peptides, with sources

See all sourcesSources
Contact
NOEN

Search peptides, guides and rules

Corrections

We keep our pages accurate and up to date. When we improve a page, we show it openly and with a date. Here you will find the corrections we have made, and how to report an error.

Last updated 1 November 2026.

How we correct errors

If we or a reader find an error, we correct it as quickly as possible. The correction is noted in the change log at the bottom of the page concerned, with a date and a short explanation. Larger corrections are also listed here.

We do not log small changes to wording or typos.

Corrections

19 October 2026: Old information from the previous version of Peptideguiden

When we rewrote the pages, we checked all information against the sources. This was corrected:

  • TB-500: The old page described a study of thymosin beta-4 in heart attack as ongoing. The study is registered as completed.[1]
  • Retatrutide: The weight loss figures now come from the published study, not from earlier reports.[2]

Found an error?

Send us a message with a link to the page and what is wrong. If you have a source, please include it. See Contact.

Sources

  1. [1]

    Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NCT05984134). ClinicalTrials.gov. 2023.

    ClinicalTrials.govRCT · n = 90

  2. [2]

    Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026.

    PMID 42814954DOIRCT · n = 2,339 · Funding or ties: Eli Lilly.